BioMarin Pharmaceutical Inc. $BMRN Shares Acquired by Strs Ohio

Strs Ohio grew its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 28.4% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 20,544 shares of the biotechnology company’s stock after buying an additional 4,544 shares during the period. Strs Ohio’s holdings in BioMarin Pharmaceutical were worth $1,129,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. Goldman Sachs Group Inc. grew its holdings in shares of BioMarin Pharmaceutical by 212.7% in the first quarter. Goldman Sachs Group Inc. now owns 1,592,963 shares of the biotechnology company’s stock valued at $112,607,000 after purchasing an additional 1,083,512 shares during the period. Covea Finance grew its holdings in shares of BioMarin Pharmaceutical by 27.3% in the second quarter. Covea Finance now owns 135,300 shares of the biotechnology company’s stock valued at $7,437,000 after purchasing an additional 29,000 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of BioMarin Pharmaceutical by 0.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,064,924 shares of the biotechnology company’s stock valued at $75,279,000 after purchasing an additional 9,837 shares during the period. Tealwood Asset Management Inc. grew its holdings in shares of BioMarin Pharmaceutical by 37.4% in the second quarter. Tealwood Asset Management Inc. now owns 21,563 shares of the biotechnology company’s stock valued at $1,185,000 after purchasing an additional 5,874 shares during the period. Finally, Perpetual Ltd purchased a new stake in shares of BioMarin Pharmaceutical in the second quarter valued at about $768,000. 98.71% of the stock is currently owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Trading Up 0.5%

NASDAQ BMRN opened at $52.80 on Thursday. The firm has a 50 day simple moving average of $54.45 and a 200-day simple moving average of $56.94. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.60 and a current ratio of 4.83. BioMarin Pharmaceutical Inc. has a one year low of $51.00 and a one year high of $73.51. The firm has a market cap of $10.14 billion, a price-to-earnings ratio of 19.85, a PEG ratio of 0.68 and a beta of 0.33.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on BMRN shares. Truist Financial dropped their price target on shares of BioMarin Pharmaceutical from $90.00 to $80.00 and set a “buy” rating for the company in a research report on Tuesday, October 28th. Royal Bank Of Canada reiterated a “sector perform” rating and set a $66.00 price target on shares of BioMarin Pharmaceutical in a research report on Tuesday, October 28th. Barclays dropped their price target on shares of BioMarin Pharmaceutical from $86.00 to $80.00 and set an “overweight” rating for the company in a research report on Tuesday, October 28th. Wells Fargo & Company dropped their price target on shares of BioMarin Pharmaceutical from $90.00 to $70.00 and set an “overweight” rating for the company in a research report on Tuesday, October 28th. Finally, UBS Group lifted their price target on shares of BioMarin Pharmaceutical from $113.00 to $114.00 and gave the company a “buy” rating in a research report on Tuesday, August 5th. Seventeen research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, BioMarin Pharmaceutical has an average rating of “Moderate Buy” and an average target price of $90.45.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.